| Literature DB >> 33912055 |
Xiaofei Shen1, Ke Cao2, Yang Zhao3, Junfeng Du4,5,6.
Abstract
Sepsis is a life-threatening condition caused by a dysregulated host response to infection. Although our understanding in the pathophysiological features of sepsis has increased significantly during the past decades, there is still lack of specific treatment for sepsis. Neutrophils are important regulators against invading pathogens, and their role during sepsis has been studied extensively. It has been suggested that the migration, the antimicrobial activity, and the function of neutrophil extracellular traps (NETs) have all been impaired during sepsis, which results in an inappropriate response to primary infection and potentially increase the susceptibility to secondary infection. On the other hand, accumulating evidence has shown that the reversal or restoration of neutrophil function can promote bacterial clearance and improve sepsis outcome, supporting the idea that targeting neutrophils may be a promising strategy for sepsis treatment. In this review, we will give an overview of the role of neutrophils during sepsis and discuss the potential therapeutic strategy targeting neutrophils.Entities:
Keywords: Signaling pathway; neutrophil; sepsis; therapeutic target; translational medicine
Year: 2021 PMID: 33912055 PMCID: PMC8072352 DOI: 10.3389/fphar.2021.644270
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1Schematic depicting current knowledge in the pathophysiological features of neutrophils during sepsis. During sepsis, both mature and immature neutrophils are generated in the bone marrow and are mobilized into peripheral blood. Transcriptional factors and environmental stimulus that determine the phenotypes of neutrophils presented in sepsis are largely unknown. Several pathophysiological features related to neutrophil function have been described, including dysregulated migration capacity, impaired antimicrobial activity, and suppression of adaptive immunity through the expression of inhibitory immune checkpoints. Neutrophil extracellular traps (NETs) in sepsis are also not controlled properly, and play an important role in tissue damage and coagulation disturbance.
Summary of therapeutic strategy targeting neutrophils.
| Target | Strategies | Outcomes | References |
|---|---|---|---|
| Neutrophil | Anti–Gr-1 | Reduces remote lung and liver injury in a mice CLP model |
|
| Leucofiltration | Improves organ function in human patients with severe sepsis |
| |
| GM-CSF | Drives the maturation and proliferation of neutrophils; Phase III study ongoing | NCT02361528; | |
| G-CSF | No improvement in clinical trial study |
| |
| Inhibition of Wip1 | Drives the maturation of neutrophils and enhances their antimicrobial function |
| |
| Anti–PD-L1 | Restores T-cell function in the mice model |
| |
| NETs | DNase I | Effective when combined with antibiotics to improve the outcome |
|
| Cl-amidine | Prevents NETs formation and improves survival in a mice CLP model |
| |
| Anti-citrullinated histone 3 | Reduces NETs and improves survival in a mice CLP model |
| |
| Anti–TREM-1 | Prevents NETosis and associated endothelial dysfunction in a mice LPS model |
| |
| Histone | Anti-histone | Improves the outcome in the LPS, TNF, and CLP mice models |
|
| Activated protein C | Failed in the clinic |
| |
| Platelet | Acetylsalicylic acid | Decreases intravascular NETosis and tissue injury |
|
| Aspirin | Ongoing clinical trial |
| |
| Anti-P2Y12 | Prevents NETosis and improves the survival in mice CLP model |
| |
| Antiplatelet factor 4 | Stabilizes NETs and prevents the release of antibacterial compounds in mice model |
|